1e
19
1
49
2
2
18
1b
1d
18
33
a2
1d
2 29
1d
25
Kyle M. Kampman, M.D.
88
a2
Professor of Psychiatry at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
28
78
3
61
Staff Physician, Veterans Affairs Medical Center, Philadelphia PA
11
Department: Psychiatry
4
1
b
1d
46
Contact information
48
4
3
3
3
2
4
b
1f
48
University of Pennsylvania
27 Center for Studies of Addiction
35 3535 market Street
Philadelphia, PA 19104
26
27 Center for Studies of Addiction
35 3535 market Street
Philadelphia, PA 19104
2e
Office: 215 746 2764
33 Fax: 1215 746 2764
24
9d
12
33 Fax: 1215 746 2764
24
13
Education:
21 9 B.A. 16 (Chemistry) c
30 Northwestern University, 1981.
21 7 MD c
2a Tulane University, 1985.
c
3
3
3
3
8a
Permanent link21 9 B.A. 16 (Chemistry) c
30 Northwestern University, 1981.
21 7 MD c
2a Tulane University, 1985.
c
2 29
21
1e
1d
24
2b
29
27
23
150 Thakrar AP, Christine PJ, Siaw-Asamoah A, Spadaro A, Faude S, Snider CK, Delgado MK, Lowenstein M, Kampman K, Perrone J, Nelson LS, Kilaru AS.: Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl. JAMA Netw Open 7: e2435895, Sep 2024.
14f Shi Z, Li X, Kampman KM, Childress AR, Wiers CE, Langleben DD.: Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder. J Clin Psychiatry 84: 22br14567, Apr 2023.
10f Stewart RE, Cardamone NC, Mandell DS, Kwon N, Kampman KM, Knudsen HK, Tjoa CW, Marcus SC.: Not in my treatment center: Leadership's perception of barriers to MOUD adoption. J Subst Abuse Treat 2023.
1af French R, Worley J, Lowenstein M, Bogner HR, Calderbank T, DePhilippis D, Forrest A, Connolly Gibbons MB, Harris RA, Heywood S, Kampman K, Mandell DS, McKay JR, Newman ST, Oslin DW, Wadden S, Wolk CB.: Adapting psychotherapy in collaborative care for treating opioid use disorder and co-occurring psychiatric conditions in primary care. Fam Syst Health 2023.
103 Dugosh KL, Lent MR, Burkley SB, Millard CMK, McKay JR, Kampman KM.: Nonopioid Substance Use among Patients Who Recently Initiated Office-based Buprenorphine Treatment. J Addict Med 2023.
e1 Krouse RA, Morales KH, Kampman KM, Chakravorty S.: The role of baseline insomnia in moderating the hypnotic properties of quetiapine. Addict Behav 2023.
16c 114. Kuijper MF, Mahajan UV, Ku S, Barbosa DAN , Alessi SM, Stein SE , Kampman KM, Bentzley BS , Halpern CH: Deep Brain Stimulation Compared With Contingency Management for the Treatment of Cocaine Use Disorders: A Threshold and Cost-Effectiveness Analysis Neuromodulation 25(2), Feb 2022.
f2 Lynch KG , Plebani, J, Spratt K, Morales M, Tamminga M, Feibush P, Kampman KM. : Varenicline for the Treatment of Cocaine Dependence J addict. J addict. Med 16(2), 2022.
f2 Lynch KG , Plebani, J, Spratt K, Morales M, Tamminga M, Feibush P, Kampman KM. : Varenicline for the Treatment of Cocaine Dependence J addict. J addict. Med 16(2), 2022.
2c
7
1d
1f
Selected Publications
18e Nosyk B, Min JE, Homayra F, Kurz M, Guerra-Alejos BC, Yan R, Piske M, Seaman SR, Bach P, Greenland S, Karim ME, Siebert U, Bruneau J, Gustafson P, Kampman K, Korthuis PT, Loughin T, McCandless LC, Platt RW, Schnepel KT, Socías ME.: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. JAMA Oct 2024.150 Thakrar AP, Christine PJ, Siaw-Asamoah A, Spadaro A, Faude S, Snider CK, Delgado MK, Lowenstein M, Kampman K, Perrone J, Nelson LS, Kilaru AS.: Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl. JAMA Netw Open 7: e2435895, Sep 2024.
14f Shi Z, Li X, Kampman KM, Childress AR, Wiers CE, Langleben DD.: Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder. J Clin Psychiatry 84: 22br14567, Apr 2023.
10f Stewart RE, Cardamone NC, Mandell DS, Kwon N, Kampman KM, Knudsen HK, Tjoa CW, Marcus SC.: Not in my treatment center: Leadership's perception of barriers to MOUD adoption. J Subst Abuse Treat 2023.
1af French R, Worley J, Lowenstein M, Bogner HR, Calderbank T, DePhilippis D, Forrest A, Connolly Gibbons MB, Harris RA, Heywood S, Kampman K, Mandell DS, McKay JR, Newman ST, Oslin DW, Wadden S, Wolk CB.: Adapting psychotherapy in collaborative care for treating opioid use disorder and co-occurring psychiatric conditions in primary care. Fam Syst Health 2023.
103 Dugosh KL, Lent MR, Burkley SB, Millard CMK, McKay JR, Kampman KM.: Nonopioid Substance Use among Patients Who Recently Initiated Office-based Buprenorphine Treatment. J Addict Med 2023.
e1 Krouse RA, Morales KH, Kampman KM, Chakravorty S.: The role of baseline insomnia in moderating the hypnotic properties of quetiapine. Addict Behav 2023.
16c 114. Kuijper MF, Mahajan UV, Ku S, Barbosa DAN , Alessi SM, Stein SE , Kampman KM, Bentzley BS , Halpern CH: Deep Brain Stimulation Compared With Contingency Management for the Treatment of Cocaine Use Disorders: A Threshold and Cost-Effectiveness Analysis Neuromodulation 25(2), Feb 2022.
f2 Lynch KG , Plebani, J, Spratt K, Morales M, Tamminga M, Feibush P, Kampman KM. : Varenicline for the Treatment of Cocaine Dependence J addict. J addict. Med 16(2), 2022.
f2 Lynch KG , Plebani, J, Spratt K, Morales M, Tamminga M, Feibush P, Kampman KM. : Varenicline for the Treatment of Cocaine Dependence J addict. J addict. Med 16(2), 2022.
2c